Profile data is unavailable for this security.
About the company
Ultimovacs ASA is a Norway-based pharmaceutical company developing immunotherapies against cancer. Ultimovacs’ technology is based on preclinical and clinical research on immunotherapies conducted at the Oslo University Hospital. Ultimovacs is advancing a broad clinical development program with clinical trials in Europe, Australia and the U.S. The Company's lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase. UV1 is being developed as a therapeutic cancer vaccine which may serve as a platform for use in combination with other immuno-oncology drugs which require an ongoing T cell response for their mode of action.
- Revenue in NOK (TTM)0.00
- Net income in NOK-179.27m
- Incorporated2011
- Employees23.00
- LocationUltimovacs ASAUllernchausseen 64OSLO 0379NorwayNOR
- Websitehttps://ultimovacs.com/